Please login to the form below
Stelara
This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.
Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara
Amgen has announced preliminary results from a phase 3 study evaluating the efficacy and safety of its drug candidate ABP 654 compared to Janssen’s Stelara in adult patients with moderate ... The study evaluated the percentage improvement from baseline
Latest news
-
J&J inks $6.5bn all-cash deal to acquire Momenta
J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.
-
J&J splashes $750m on anti-inflammatory drug bermekimab
J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing
-
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.
-
Janssen files Tremfya for psoriatic arthritis in Europe
First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three
-
CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal
showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.
More from news
Approximately 15 fully matching, plus 74 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were
-
Taking a strategic approach
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
-
Back to the future
Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Moderna to launch Innovation and Technology Center in the UK
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- VMLY&R wins two Grand Prix awards at Cannes Lions International Festival of Creativity 2022
- How digital health is changing the relationship between patients and health providers | OPEN Health
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Roche shares new positive Ocrevus data for MS patients
- Six UK universities receive grant for research into motor neurone disease
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
